Arias F, Pineda J, Johnson L W
Am J Obstet Gynecol. 1979 Apr 15;133(8):894-8. doi: 10.1016/0002-9378(79)90308-9.
In an effort to understand the biochemical changes responsible for the decreased incidence of neonatal RDS observed in premature infants delivered after maternal glucocorticoid therapy we have compared quantitative changes in L/S ratio and qualitative changes in dipalmitoyl lecithin in serial amniotic fluid samples from 20 pregnant women treated with betamethasone and 11 patients who had repeated amniocentesis at similar gestational age but did not receive glucocorticoids. Initial L/S ratio values were not significantly different between treated (1.24 +/- 0.24 [S.D.]) and control (1.09 +/- 0.29 [S.D.]) groups but the values obtained within 1 week after therapy (1.49 +/- 0.21 [S.D.]) were significantly higher (t=3.8; p less than 0.01) than those obtained after a similar period in the untreated group (1.24+/- 0.29 [S.D.]). However, only one of the treated patients reached a mature L/S ratio (2.0 or more). Simultaneously, 10 of 17 treated patients exhibited increases in the amount of dipalmitoyl lecithin within the first week after treatment, wheras no change was detected in serial samples from six control patients (p = 0.016). These results indicate that qualitative changes in amniotic fluid lecithin composition are a part of the fetal response to glucocorticoids which may be responsible for the decreased incidence of RDS observed after treatment.
为了了解母体糖皮质激素治疗后早产婴儿新生儿呼吸窘迫综合征(RDS)发病率降低的生化变化,我们比较了20例接受倍他米松治疗的孕妇和11例在相似孕周重复进行羊膜腔穿刺但未接受糖皮质激素治疗的患者连续羊水样本中卵磷脂/鞘磷脂(L/S)比值的定量变化以及二棕榈酰卵磷脂的定性变化。治疗组(1.24±0.24[标准差])和对照组(1.09±0.29[标准差])的初始L/S比值无显著差异,但治疗后1周内获得的值(1.49±0.21[标准差])显著高于未治疗组在相似时间段后获得的值(1.24±0.29[标准差])(t = 3.8;p<0.01)。然而,治疗组中只有1例患者达到了成熟的L/S比值(2.0或更高)。同时,17例治疗患者中有10例在治疗后第一周内二棕榈酰卵磷脂含量增加,而6例对照患者的连续样本中未检测到变化(p = 0.016)。这些结果表明羊水卵磷脂成分的定性变化是胎儿对糖皮质激素反应的一部分,这可能是治疗后观察到RDS发病率降低的原因。